Detalles de la búsqueda
1.
A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness.
Antimicrob Agents Chemother
; 68(4): e0127323, 2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38376227
2.
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
JAMA
; 327(13): 1236-1246, 2022 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35285853
3.
Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation.
Am J Transplant
; 20(6): 1703-1711, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31883426
4.
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Antimicrob Agents Chemother
; 63(4)2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30745392
5.
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
J Antimicrob Chemother
; 74(3): 710-717, 2019 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30541077
6.
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection.
J Viral Hepat
; 26(6): 675-684, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30739366
7.
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
J Viral Hepat
; 26(9): 1127-1138, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31108015
8.
Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.
Eur J Clin Pharmacol
; 75(5): 665-675, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30680407
9.
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor.
Antimicrob Agents Chemother
; 61(12)2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28947470
10.
No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
Eur J Clin Pharmacol
; 73(5): 593-600, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28233047
11.
Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.
Antimicrob Agents Chemother
; 59(11): 6922-9, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26303801
12.
Efficiency of cell-free and cell-associated virus in mucosal transmission of human immunodeficiency virus type 1 and simian immunodeficiency virus.
J Virol
; 87(24): 13589-97, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24109227
13.
Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial.
Infect Dis Ther
; 13(2): 401-411, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38291279
14.
Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.
J Virol
; 86(13): 7052-9, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22532675
15.
Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection.
J Virol
; 86(10): 5877-84, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22419810
16.
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA.
Infect Dis Ther
; 12(2): 607-621, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36629998
17.
Population pharmacokinetics and exposure-response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID-19.
CPT Pharmacometrics Syst Pharmacol
; 12(6): 853-864, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36922886
18.
Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial.
Open Forum Infect Dis
; 10(8): ofad354, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37577112
19.
Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses.
J Virol
; 85(11): 5465-75, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21450829
20.
Epitope-specific CD8+ T lymphocytes cross-recognize mutant simian immunodeficiency virus (SIV) sequences but fail to contain very early evolution and eventual fixation of epitope escape mutations during SIV infection.
J Virol
; 85(8): 3746-57, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21307185